Replies to post #244195 on Biotech Values

[swampboots]

I am waiting for a single cancer house to publish something like this:
We fired our PR staff waxing versions of possible success, as we are now the first to announce that regarding our leading drug, our initiatives beyond any scientific doubt support announcing a complete enduring 100% cure rate with no side effects . We also wish to announce ala Marlon Brando earlier, we will not accept any awards or
participate in promoting any non-scientific praise.

[swampboots]

The absolute knowledge that no drug can be proven to ever fail under any future circumstance aways imbeds a (marketable) positive bias after dismal drug trial failures.
Exhibit A:
RE: Pembrolizumab, sold under the brand name Keytruda, now first line treatment of numerous metastatic cancers,( having generated over 17 billion in revenues to date ). In early 2010, Merck terminated development and began preparing to out-license it...................in short it was only the knowledge of limiting its use with patients matching biomarker criteria which made Merck start from almost scratch to get into this field in major depth, as this drug only came as an incidental package in buyout from Schering-Plough, and in 2013 for its first time, Merck applied for and won a breakthrough therapy designation for it.

https://en.wikipedia.org/wiki/Pembrolizumab

[DewDiligence]

ADXS reverse-merges with—(private)—Biosight Ltd:

https://www.globenewswire.com/news-release/2023/07/27/2712158/0/en/Ayala-Pharmaceuticals-and-Biosight-Enter-into-Definitive-Merger-Agreement.html

Under the terms of the merger agreement, upon completion of the merger, ownership of the combined company will be split, with 55% ownership going to Biosight stockholders and 45% going to Ayala stockholders.

… Biosight is a private clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight’s lead product, aspacytarabine (BST-236), is an innovative proprietary anti-metabolite designed to address unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity.

Although this deal is structured as a straight-up merger (i.e. the name and ticker symbol are not changing), it is functionally a reverse-merger insofar as Biosight’s shareholders will end up owning 55% of the equity in the merged company. As such, this is ADXS’ second reverse-merger in less than a year (#msg-170233693).